IKZF2 Degrader Compounds for Tumor-Selective Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments targeting regulatory T-cells (Tregs) in tumors, such as anti-CTLA4 antibodies, cause systemic activation of T-effector cells, leading to excessive toxicity and limiting therapeutic utility in cancer treatment.
Innovation Solution
Development of IKZF2-specific degraders, particularly 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds, which selectively reduce IKZF2 protein levels in Tregs, focusing the immune response on tumor sites without activating T-effector cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CTLA4 antibodies are used to target regulatory T-cells in tumors, then the immune response is enhanced, but systemic activation of T-effector cells occurs leading to excessive toxicity
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for IKZF2 in regulatory T-cells within the tumor microenvironment. The compounds selectively degrade IKZF2 protein in Tregs at the tumor site while leaving T-effector cells unaffected, thereby enhancing anti-tumor immunity locally without causing systemic activation and toxicity.
Solution Approach 2:
The patent segments the immune response by specifically targeting the IKZF2 transcription factor in regulatory T-cells, separating the modulation of Treg function from T-effector cell activation. This selective degradation approach divides the immune modulation effect, achieving tumor-specific immune enhancement without pan-immune activation.
2Object-affected harmful factors
If IKZF2-specific degraders are developed to selectively reduce IKZF2 protein levels in Tregs, then systemic toxicity is reduced, but the complexity of achieving selective degradation increases
Solution Approach 1:
The patent uses an intermediary mechanism by employing small molecule degraders that act as mediators between the therapeutic goal and the molecular target. These compounds bind to IKZF2 and recruit cellular degradation machinery (proteasome system), selectively reducing IKZF2 protein levels in Tregs without directly activating T-effector cells, thus achieving selectivity through a molecular intermediary.
Solution Approach 2:
The patent applies parameter changes by modifying the molecular structure of the compounds to achieve optimal selectivity for IKZF2 over other Ikaros family members. By adjusting structural parameters such as the core isoindolinone scaffold and substituent groups, the compounds achieve selective binding and degradation of IKZF2 with appropriate potency and selectivity parameters.
Data Source
AI summary
The present disclosure provides a compound of Formula (I′):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.